Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Achilles Therapeutics plcACHL-0.610.000.300.76-44.22%-8.42%54.81$0.90$0.55300$0.985

Detail of Achilles Therapeutics plc

 
CEO
Dr. Iraj Ali Ph.D.
Employees
204
Industry
Biotechnology
Sector
Healthcare
Market cap
$40M

Company details

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Achilles Therapeutics plc
ACHL • XNGS • US
$0.985
+0.09 (10.67%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.63
Margin profit
0.00%
52 week low
$0.6851
52 week high
$1.57
50-day simple moving average
$0.94
200-day simple moving average
$0.90
Percent held by insiders
6.52%
Percent held by institutions
62.46%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
ACHL +10.67%
eps change
ACHL 0.00%